12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dulaglutide: Phase III data

Top-line data from the double-blind, international Phase III AWARD-5 trial in 1,098 Type II diabetics on metformin showed that once-weekly 1.5 mg subcutaneous dulaglutide met the primary endpoint of non-inferiority to Januvia sitagliptin in reducing HbA1c from baseline to week 52. Additionally, the trial was designed to assess superiority of...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >